Write your message
Volume 4, Issue 3 (Summer 2019)                   J Obstet Gynecol Cancer Res 2019, 4(3): 120-126 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Behtash N, Akhavan S. The Outcomes of Uterine Sarcoma: A Case-series of 5-Years Survey. J Obstet Gynecol Cancer Res. 2019; 4 (3) :120-126
URL: http://jogcr.com/article-1-247-en.html
1- Professor, Department of Gynecology Oncology, Tehran University of Medical Sciences, Tehran, Iran
Associate Professor, Department of Gynecology Oncology, Tehran University of Medical Sciences, Tehran, Iran , setare_akh@yahoo.com
Abstract:   (92 Views)

Uterine sarcomas (US) are relatively rare malignant tumor of the uterine mesenchymal tumor. The present study evaluated the outcomes of patients with different types of uterine sarcoma in Iranian women for the first time during a 5-years survey. During 2015-2019, a case series of twenty-three patients of US (four cases of leiomyosarcoma (LMS), nine cases of endometrial stromal sarcoma (ESS), seven cases of carcinosarcoma (CS), and three cases of adenosarcoma (AS)) were studied. One case of AS needed adjuvant radiotherapy and a recurrence was occurred in this case four years later. Two cases of CS have died during study period. All of ESS cases were alive by the study duration. One case who did not receive radio/chemotherapy experienced a bronchial recurrence after 8-years of ESS diagnosis Immunohistochemistry test on tumoral cells of three patients for vimentin+Ki67, BCL2+CD64+Ki67, ER+PR+WT1+Ki67 expressions were 30%, 30%, 15% respectively. Two cases of CS died during the study period. Even with multimodalities of treatment, the prognosis of uterine sarcoma is still poor and early diagnosis seems to improve the prognosis of the patients.

     

 Two cases of CS died during the study period. Even with multimodalities of treatment, the prognosis of uterine sarcoma is still poor and early diagnosis seems to improve the prognosis of the patients.


Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2020/01/9 | Accepted: 2020/01/27 | Published: 2020/01/27

References
1. Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best practice & research Clinical obstetrics & gynaecology. 2012;26(2):257-66. [DOI:10.1016/j.bpobgyn.2011.08.002] [PMID] [DOI:10.1016/j.bpobgyn.2011.08.002] [PMID]
2. Suzuki A, Aoki M, Miyagawa C, Murakami K, Takaya H, Kotani Y, et al., editors. Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma using Magnetic Resonance Images: A Literature Review. Healthcare; 2019: Multidisciplinary Digital Publishing Institute. [DOI:10.3390/healthcare7040158] [PMID] [PMCID] [DOI:10.3390/healthcare7040158] [PMID] [PMCID]
3. Wu T-I, Yen T-C, Lai C-H. Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Practice & Research Clinical Obstetrics & Gynaecology. 2011;25(6):681-9. [DOI:10.1016/j.bpobgyn.2011.07.002] [PMID] [DOI:10.1016/j.bpobgyn.2011.07.002] [PMID]
4. Ghaemmaghami F, Karimi-Zarchi M, Gilani MM, Mousavi A, Behtash N, Ghasemi M. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran. Asian Pac J Cancer Prev. 2008;9(3):421-6.
5. Barney BM, Petersen IA, Dowdy SC, Bakkum-Gamez JN, Haddock MG. Long-term outcomes with intraoperative radiotherapy as a component of treatment for locally advanced or recurrent uterine sarcoma. International Journal of Radiation Oncology* Biology* Physics. 2012;83(1):191-7. [DOI:10.1016/j.ijrobp.2011.06.1960] [PMID] [DOI:10.1016/j.ijrobp.2011.06.1960] [PMID]
6. Koivisto-Korander R, Butzow R, Koivisto A-M, Leminen A. Clinical Outcome and Prognostic Factors in 100 Cases of Uterine Sarcoma: Experience in Helsinki University Central Hospital 1990-2001. Obstetrical & Gynecological Survey. 2009;64(1):25-6. [DOI:10.1097/01.ogx.0000340772.16228.30] [DOI:10.1097/01.ogx.0000340772.16228.30]
7. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. The lancet oncology. 2009;10(12):1188-98. [DOI:10.1016/S1470-2045(09)70226-8] [DOI:10.1016/S1470-2045(09)70226-8]
8. Mowers EL, Skinner B, McLean K, Reynolds RK. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. Journal of minimally invasive gynecology. 2015;22(4):601-6. [DOI:10.1016/j.jmig.2015.01.007] [PMID] [DOI:10.1016/j.jmig.2015.01.007] [PMID]
9. Thomas MB, Keeney GL, Podratz KC, Dowdy SC. Endometrial stromal sarcoma: treatment and patterns of recurrence. International Journal of Gynecologic Cancer. 2009;19(2):253-6. [DOI:10.1111/IGC.0b013e3181999c5f] [PMID] [DOI:10.1111/IGC.0b013e3181999c5f] [PMID]
10. Alcazar JL, Galvan R. Three-dimensional power Doppler ultrasound scanning for the prediction of endometrial cancer in women with postmenopausal bleeding and thickened endometrium. American journal of obstetrics and gynecology. 2009;200(1):44. e1-. e6. [DOI:10.1016/j.ajog.2008.08.027] [PMID] [DOI:10.1016/j.ajog.2008.08.027] [PMID]
11. Arend R, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecologic oncology. 2010;119(2):305-8. [DOI:10.1016/j.ygyno.2010.07.001] [PMID] [DOI:10.1016/j.ygyno.2010.07.001] [PMID]
12. Burghaus S, Halmen S, Gass P, Mehlhorn G, Schrauder MG, Lux MP, et al. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. Archives of gynecology and obstetrics. 2016;294(2):343-51. [DOI:10.1007/s00404-015-3993-6] [PMID] [DOI:10.1007/s00404-015-3993-6] [PMID]
13. Potikul C, Tangjitgamol S, Khunnarong J, Srijaipracharoen S, Thavaramara T, Pataradool K. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand. Asian Pac J Cancer Prev. 2016;17(4):1759-67. [DOI:10.7314/APJCP.2016.17.4.1759] [PMID] [DOI:10.7314/APJCP.2016.17.4.1759] [PMID]
14. Kimyon Comert G, Turkmen O, Karalok A, Basaran D, Bulbul D, Turan T. Therapy Modalities, Prognostic Factors, and Outcome of the Primary Cervical Carcinosarcoma: Meta-analysis of Extremely Rare Tumor of Cervix. Int J Gynecol Cancer. 2017;27(9):1957-69. [DOI:10.1097/IGC.0000000000001086] [PMID] [DOI:10.1097/IGC.0000000000001086] [PMID]
15. Cui RR, Wright JD, Hou JY. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. BJOG. 2017;124(7):1028-37. [DOI:10.1111/1471-0528.14579] [PMID] [DOI:10.1111/1471-0528.14579] [PMID]
16. Kodama K, Sonoda K, Kijima M, Yamaguchi S, Yagi H, Yasunaga M, et al. Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10‐year experience of a single institute. Asia‐Pacific Journal of Clinical Oncology. 2019. [DOI:10.1111/ajco.13286] [PMID] [DOI:10.1111/ajco.13286] [PMID]
17. Li Y RH, Wang J. . Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. . BMC Cancer. 2019;19(1):697. [DOI:10.1186/s12885-019-5879-7] [PMID] [PMCID] [DOI:10.1186/s12885-019-5879-7] [PMID] [PMCID]
18. Li Y, Ren H, Wang J. Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. BMC cancer. 2019;19(1):697-. [DOI:10.1186/s12885-019-5879-7] [PMID] [PMCID] [DOI:10.1186/s12885-019-5879-7] [PMID] [PMCID]
19. Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013;20(7):2364-72. [DOI:10.1245/s10434-012-2834-0] [PMID] [PMCID] [DOI:10.1245/s10434-012-2834-0] [PMID] [PMCID]
20. Kyriazoglou A, Liontos M, Ziogas DC, Zagouri F, Koutsoukos K, Tsironis G, et al. Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. BMC cancer. 2018;18(1):1247-. [DOI:10.1186/s12885-018-5156-1] [PMID] [PMCID] [DOI:10.1186/s12885-018-5156-1] [PMID] [PMCID]
21. Yu T, Kim HJ, Wu H-G, Ha SW, Song Y-S, Park N-H, et al. Outcome analysis in patients with uterine sarcoma. Radiat Oncol J. 2015;33(1):29-35. [DOI:10.3857/roj.2015.33.1.29] [PMID] [PMCID] [DOI:10.3857/roj.2015.33.1.29] [PMID] [PMCID]
22. Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E, et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer. 2015;25(2):279-87. [DOI:10.1097/IGC.0000000000000347] [PMID] [DOI:10.1097/IGC.0000000000000347] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.